April 2010

Thursday, April 15, 2010 to Friday, April 16, 2010

The life sciences industry is operating in a more litigious and aggressive environment than ever before. There are stepped up enforcement initiatives from the FDA, FTC and DOJ. In the last couple of months there has also been a movement to strike many defensive strategies for litigation such as the Riegel verdict as well as Iqbal. The motion to throw out preemption could lead to larger scrutiny on the drug labeling process for many pharmaceuticals. The costs associated with drug and medical device litigation is huge and in today’s economic climate it is imperative that pharmaceutical and medical device companies look at strategies to minimize their cost from the exorbitant cost of e-discovery to the cost of engaging outside counsel. Even if a case is successfully defended, the need for extensive expert evidence and detailed discoveries can push legal costs of even routine product liability actions into the millions of dollars. Many are looking to negotiate rates and have alternative fee arrangement agreements in place or different models of fees to help with the cost of litigation. This Drug and Medical Device Litigation Conference builds on out last five successful events, providing timely, best-practices advice to corporate counsel in an industry under attack. Responding to market demand, this event offers fresh insights into discrete litigation issues; taking a more advanced approach to specific areas of contention, rather than walking corporate counsel through the litigation process. The Conference also addresses key litigation prevention and regulatory compliance strategies.